Tailored Dosimetry Improves Treatment Outcomes in Hepatocellular Carcinoma with Yttrium-90 Resin Microsphere Radioembolization - Report - MDSpire

Tailored Dosimetry Improves Treatment Outcomes in Hepatocellular Carcinoma with Yttrium-90 Resin Microsphere Radioembolization

  • By

  • Ettore di Gaeta

  • Makoto Taninokuchi Tomassoni

  • Francesca Calabrese

  • Giovanni Matassa

  • Annarita Savi

  • Carla Canevari

  • Patrizia Magnani

  • Giovanna Pepe

  • Stephanie Steidler

  • Francesca Ratti

  • Federica Cipriani

  • Margherita Rimini

  • Andrea Casadei-Gardini

  • Lorenzo Braccischi

  • Maria Adriana Cocozza

  • Lidia Strigari

  • Giuseppe Della Gala

  • Arber Golemi

  • Elisa Lodi Rizzini

  • Stefano Fanti

  • Matteo Cescon

  • Matteo Serenari

  • Fabio Piscaglia

  • Maria Cristina Morelli

  • Arturo Chiti

  • Cristina Mosconi

  • Francesco De Cobelli

  • April 28, 2026

  • 0 min

Share

Clinical Report: Tailored Dosimetry Improves Treatment Outcomes in HCC

Overview

This study evaluates the efficacy of tailored dosimetry in patients with hepatocellular carcinoma (HCC) treated with Yttrium-90 resin microspheres. Findings indicate that personalized dosimetry significantly enhances overall survival and objective response rates in various stages of HCC.

Background

Hepatocellular carcinoma (HCC) presents significant treatment challenges, particularly in achieving complete responses while preserving liver function. Transarterial radioembolization (TARE) with Yttrium-90 has emerged as a promising non-surgical option, especially for patients not suitable for surgical interventions. Recent guidelines emphasize the importance of personalized dosimetry to optimize treatment outcomes.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

  • Personalized dosimetry improves overall survival (OS) and objective response rate (ORR) in HCC patients.
  • The study included 64 patients treated with Yttrium-90 resin microspheres.
  • Radiological response was assessed using modified Response Evaluation Criteria in Solid Tumors (mRECIST) at 3 months post-treatment.
  • Threshold dose (Dmean) was evaluated as a surrogate endpoint for efficacy.
  • Safety and correlation to different doses were also assessed.

Clinical Implications

Clinicians should consider implementing personalized dosimetry protocols for TARE in HCC patients to enhance treatment efficacy. This approach may lead to improved survival rates and better management of tumor responses across various disease stages.

Conclusion

Tailored dosimetry represents a significant advancement in the treatment of HCC with Yttrium-90 resin microspheres, potentially leading to better patient outcomes. Further studies are warranted to solidify these findings and refine treatment protocols.

References

  1. European Radiology, 2025 -- Frontline Use of Yttrium-90 Glass Microsphere Radioembolization for Hepatocellular Carcinoma with Localized Portal Vein Invasion
  2. The ASCO Post, 2021 -- FDA Approves TheraSphere Y-90 Glass Microspheres for Unresectable Hepatocellular Carcinoma
  3. The ASCO Post, 2025 -- Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC
  4. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma, 2025
  5. The ASCO Post — FDA Approves TheraSphere Y-90 Glass Microspheres for Unresectable Hepatocellular Carcinoma
  6. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

Original Source(s)

Tailored Dosimetry Improves Treatment Outcomes in Hepatocellular Carcinoma with Yttrium-90 Resin Microsphere Radioembolization

  • by Ettore di Gaeta, Makoto Taninokuchi Tomassoni, Francesca Calabrese, Giovanni Matassa, Annarita Savi, Carla Canevari, Patrizia Magnani, Giovanna Pepe, Stephanie Steidler, Francesca Ratti, Federica Cipriani, Margherita Rimini, Andrea Casadei-Gardini, Lorenzo Braccischi, Maria Adriana Cocozza, Lidia Strigari, Giuseppe Della Gala, Arber Golemi, Elisa Lodi Rizzini, Stefano Fanti, Matteo Cescon, Matteo Serenari, Fabio Piscaglia, Maria Cristina Morelli, Arturo Chiti, Cristina Mosconi, Francesco De Cobelli

  • April 28, 2026

Related Content

CT-Based Assessment of Malignancy Risk in Part-Solid Pulmonary Nodules Utilizing Vascular Distortion and Interruption Analysis

Automated Deep Learning Segmentation and CT Elastography Radiomics for Predicting Lymph Node Metastasis Near the Right Recurrent Laryngeal Nerve in Esophageal Cancer Preoperatively

HMC-transducer: hierarchical mamba-CNN transducer for robust liver tumor segmentation